Hormone Therapy Has More Long-term Impact on Quality of Life Than Chemo, Study Suggests

Hormone Therapy Has More Long-term Impact on Quality of Life Than Chemo, Study Suggests
Challenging conventional wisdom, new findings suggest that hormone therapy may have a greater impact than chemotherapy on long-term quality of life in women with breast cancer, particularly those who have gone through menopause. The study, "Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis," was published in Annals of Oncology. Despite its proven benefits in fighting cancer, chemotherapy is widely known for its negative effects on quality of life, particularly throughout treatment and in the immediate post-chemo periods. Aiming to avoid chemotherapy toxicities, treatments for hormone receptor (HR)-positive breast cancer patients have changed remarkably in the past years, with hormone therapies gradually replacing chemotherapy regimens. Hormone therapies are accompanied by their own side effects and deterioration in quality of life, although clinical trials suggest only a modest effect. However, few studies have directly compared the effect of chemotherapy and hormone therapy on patients' quality of life. To address this, researchers at Institut Gustave Roussy in France used data from a prospective cohort study called CANTO (NCT01993498), which was aimed at quantifying the toxicity of localized breast cancer treatments up to five years after treatment. CANTO's participants were treated primarily with surgery and, in some cases, chemotherapy and/or radiotherapy. About three-quarters of the participants were treated with hormone therapy for at least five years. Researchers analyzed quality of life data for 4,262 women, 2,675 of whom had gone through menopause. Quality of life was measured at diagnosis, one year after diagnosis, and one year after th
Subscribe or to access all post and page content.